Role of Iron Chelators, Hydroxyurea, and Splenectomy on Serum Total Antioxidant Capacity in Î²-Thalassemia
BACKGROUND: Iron overload is the main cause of oxidative stress in beta-thalassemia (Î²T) by the increased production of free radicals and reactive oxygen species. Antioxidants counteract the toxic effects of oxidative stress.
AIM: This study aims to evaluate the total antioxidant capacity (TAC) and the possible impact of splenectomy, iron chelators, and hydroxyurea (hydra) on serum level of TAC.
MATERIALS AND METHODS: Fifty children and adolescents with Î²T were studied in comparison to 25 healthy age- and sex-matched subjects. Complete medical history, clinical examination, and laboratory assessment of serum TAC, ferritin, hepcidin, and hemoglobin (Hb) were carried out.
RESULTS: There was no statistically significant difference between the three groups; thalassemia major (TM), thalassemia intermedia (TI), and controls as regard age and sex. Î²-TM patients had significantly higher serum ferritin, serum hepcidin, and serum TAC (p < 0.000, 0.002, and 0.000, respectively) than controls. Î²-TI patients had significantly higher serum ferritin and serum TAC (p < 0.000) than controls. Serum TAC was lower in children with splenectomy, but this difference was not statistically significant. In addition, we observed no statistically significant difference in serum TAC of patients under different (deferasirox or deferiprone) medication. Serum TAC concentration was significantly higher in patients taking hydroxyurea (hydra) (p < 0.010).
CONCLUSIONS: The study showed an increased level of serum TAC in patients with Î²-T in comparison with controls. Serum TAC was also increased in those taking hydroxyurea, however, it was low in Î²T patients under regular chelation therapy, while splenectomy had no significant effect on serum TAC.
Plum Analytics Artifact Widget Block
Ismail NA, Habib SA, Talaat AA, Mostafa NO, Elghoroury EA. The relation between serum hepcidin, ferritin, hepcidin: Ferritin ratio, hydroxyurea and splenectomy in children with Î²-thalassemia. Open Access Maced J Med Sci. 2019;7:2434-9. https://doi.org/10.3889/oamjms.2019.636 PMid:31666842
Ismail AM, Moustafa NO, Habib SA, El Ghaffar Mohammad NA, Kafoury MR, Ahmed A. Talaat impact of splenectomy and chelating agents on serum cystatin C levels in egyptian children with beta-thalassemia. Aust J Basic Appl Sci. 2012;6:85-9.
Vichinsky E, Butensky E, Fung E, Hudes M, Theil E, Ferrell L, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol. 2005;80(1):70-4. https://doi.org/10.1002/ajh.20402 PMid:16138345
Pavlova LE, Savov VM, Petkov HG, Charova IP. Oxidative stress in patients with beta-thalassemia major. Prilozi. 2007;28(1):145-54. PMid:17921925
Tsamesidis I, Fozza C, Vagdatli E, Kalpaka A, Cirotto C, Pau MC, et al. Total antioxidant capacity in Mediterranean Î²-thalassemic patients. Adv Clin Exp Med. 2017;26(5):789-93. https://doi. org/10.17219/acem/63746 PMid:29068574
Pilo F, Angelucci E. A storm in the niche: Iron, oxidative stress and haemopoiesis. Blood Rev. 2018;32(1):29-35. https://doi. org/10.1016/j.blre.2017.08.005 PMid:28847531
Vanella A, Campisi A, Castorina C, Sorrenti V, Attaguile G, Samperi P, et al. Antioxidant enzymatic systems and oxidative stress in erythrocytes with G6PD deficiency: Effect of deferoxamine. Pharmacol Res. 1991;24(1):25-31. https://doi. org/10.1016/1043-6618(91)90061-2 PMid:1946141
Marrocco I, Altieri F, Peluso I. Measurement and clinical significance of biomarkers of oxidative stress in humans. Oxid Med Cell Longev. 2017;2017:6501046. https://doi. org/10.1155/2017/6501046 PMid:28698768
Bazvand F, Shams S, Borji Esfahani M, Koochakzadeh L, Monajemzadeh M, Ashtiani MT, et al. Total antioxidant status in patients with major Î²-thalassemia. Iran J Pediatr. 2011;21(2):159-65. PMid:23056782
Tsamesidis I, Pantaleo A, Pekou A, Gusani A, Iliadis S, Makedou K, et al. Correlation of oxidative stress biomarkers and hematological parameters in blood cancer patients from Sardinia, Italy. Int J Hematol Oncol Stem Cell Res. 2019;17(2):50-7. https://doi.org/10.18502/ijhoscr.v13i2.688
AkÃ§a H, Polat A, Koca C. Determination of total oxidative stress and total antioxidant capacity before and after the treatment of iron-deficiency anemia. J Clin Lab Anal. 2013;27(3):227-30. https://doi.org/10.1002/jcla.21589 PMid:23440750
Fibach E, Rachmilewitz EA. The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia. Ann N Y Acad Sci. 2010;1202:10-6. PMid:20712766
Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V. Method for the measurement of antioxidant activity in human fluids. J Clin Pathol. 2001;54(5):356-61. https://doi.org/10.1136/ jcp.54.5.356 PMid:11328833
Kampa M, Nistikaki A, Tsaousis V, Maliaraki N, Notas G, Castanas E. A new automated method for the determination of the total antioxidant capacity (TAC) of human plasma, based on the crocin bleaching assay. BMC Clin Pathol. 2002;2(1):3. https://doi.org/10.1186/1472-6890-2-3 PMid:12197944
Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;37(4):277-85. https://doi. org/10.1016/j.clinbiochem.2003.11.1015 PMid:15003729
Karakas Z, Yilmaz Y, Celik DD, Annayev A, Demirel S, Kuruca SE. Total oxidant and antioxidant capacity in patients with transfusion dependent and nondependent beta thalassemia. Blood. 2015;126(23):4573. https://doi.org/10.1182/blood. v126.23.4573.4573
Cakmak A, Soker M, Koc A, Aksoy N. Prolidase activity and oxidative status in patients with thalassemia major. J Clin Lab Anal. 2010;24(1):6-11. https://doi.org/10.1002/jcla.20361 PMid:20087956
Shazia Q, Mohammad ZH, Rahman T, Shekhar HU. Correlation of oxidative stress with serum trace element levels and antioxidant enzyme status in beta thalassemia major patients: A review of the literature. Anemia. 2012;2012:270923. https:// doi.org/10.1155/2012/270923 PMid:22645668
Metwalley KA, El-Saied AR. Glucose homeostasis in Egyptian children and adolescents with Î²-thalassemia major: Relationship to oxidative stress. Indian J Endocrinol Metab. 2014;18(3):333-9. https://doi.org/10.4103/2230-8210.131169 PMid:24944927
RodrÃguez Galindo C, Ortega Aramburu JJ, Alonso JL, Albisu M, CasaldÃ¡liga J, DÃaz de Heredia C, et al. Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major. Med Clin (Barc). 1994;102(19):721-4. PMid:8041200
Copyright (c) 2020 Ahmed Talaat, Nagwa Abdallah Ismail, Sonia Adolf Habib, Hisham A. Orban (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All rights reserved.